This article is more than 5 years old. Information may no longer be current.
UGT2B17, UGT2B28 not associated with prostate carcinogenesis
AACR 100th Annual Meeting
The genes UGT2B17 and UGT2B28 — UDP glucuronosyltransferase 2 family polypeptides B17 and B28 — did not confer risk for prostate cancer either alone or in combination, according to the results of a study involving 269 men from the Tyrol Early PCA Detection Program.
Findings of earlier studies suggested an increased risk for prostate cancer associated with copy number changes in UGT2B17; however, based on their findings, Sunita R. Setlur, PhD, a pathologist at Brigham and Women’s Hospital in Boston, and colleagues have concluded that the genes do not play a major role in prostate carcinogenesis.
Setlur presented the results at the AACR 100th Annual Meeting in Denver.
The researchers collected samples from 156 men with prostate cancer and 113 healthy participants. PSA threshold for patients was age dependent and as low as 1.25 ng/mL. The researchers characterized all samples for copy number changes for the genes UGT2B17, UGT2B7 and UGT2B28.
The overall incidence of homozygous deletion was 11.9% for UGT2B17 and 3.4% for UGT2B28. For hemizygous deletion, the overall incidence for UGT2B17 was 39.8% and 19.9% for UGT2B28.
“We did not see, as evidenced by the P values, any association between the deletion polymorphism of B17 and B28 with cancer,” Setlur said. The researchers did not detect copy number changes in UGT2B7. – by Jason Harris
For more information: